替加环素治疗颅内耐药菌感染的研究进展

发布时间：2018-11-02 08:14

【摘要】：目的:关注替加环素治疗颅内耐药菌感染的研究进展。方法:查阅近年来国内外相关文献,对替加环素治疗颅内耐药菌感染的9例病例进行归纳和分析。结果与结论:替加环素治疗颅内耐药菌感染多用于革兰阴性耐药菌感染,给药方式主要为静脉给药,维持剂量多为50 mg,bid,大多与其他抗菌药物联用。由于替加环素较大的表观分布容积和较差的血脑屏障透过能力,导致脑脊液中的药物浓度远低于治疗要求,从药理学上很难解释替加环素在合并用药方案中的有效性。提高替加环素在脑脊液中的药物浓度的给药方式有待进一步研究。
[Abstract]:Objective: to investigate the progress of tigicycline in the treatment of intracranial drug-resistant bacteria infection. Methods: 9 cases of intracranial drug-resistant bacteria infection treated by tegacycline were summarized and analyzed by referring to the relevant literature at home and abroad in recent years. Results and conclusion: tigicycline was used in the treatment of intracranial drug-resistant bacteria infection, the main way of administration was intravenous administration, and the maintenance dose of 50 mg,bid, was mostly combined with other antimicrobial agents. Because of the large apparent distribution volume of tegicycline and poor blood-brain barrier permeability, the drug concentration in cerebrospinal fluid is much lower than the therapeutic requirement. It is difficult to explain the pharmacological efficacy of tegacycline in combined drug treatment. The way to increase the concentration of tegicycline in cerebrospinal fluid needs further study.
【作者单位】：首都医科大学附属北京天坛医院药学部;首都医科大学化学生物学与药学院;
【基金】：国家自然科学基金资助项目(No.81301118) 多肽及小分子药物北京市重点实验室开放课题计划(No.2014DTYW03) 首都医科大学学生科研创新项目(No.XSKY2015181)
【分类号】：R741

【参考文献】